MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from november
2025 convertible...
$12,000,000
Proceeds from the
issuance of common...
$7,998,826
Proceeds from
at-the-market sales of common...
$7,013,162
Proceeds from the
issuance of common...
$4,510,001
Proceeds from exercise of
common warrants
$3,318,879
Proceeds from common
stock issued through...
$90,332
Proceeds from exercise of
pre-funded warrants
$500
Net cash provided by
financing activities
$25,135,255
Canceled cashflow
$9,796,445
Net change in cash
and cash...
$5,814,592
Canceled cashflow
$19,320,663
Repayment of november 2023
convertible notes,...
$6,765,000
Issuance costs-Warrants
Nine
$930,132
Issuance costs-Warrants
Eight
$804,940
Issuance costs for
november 2025...
$718,528
Repayment of note payable
$367,450
Issuance costs for
at-the-market sales of common...
$210,395
Amortization of debt issuance
costs and discount
$1,387,050
Share-based compensation
expense
$790,145
Amortization of right-of-use
assets
$508,422
Prepaid and other assets
-$496,902
Accrued expenses
$474,724
Accounts payable
$334,829
Depreciation
$295,859
Accretion of paid-in-kind
interest
$132,140
Loss on fixed asset
dispositions
-$62,650
Amortization
$46,175
Other noncash items
-$5,724
Net cash used in
operating activities
-$18,690,565
Net cash used in
investing activities
-$630,098
Canceled cashflow
$4,534,620
Net loss
-$18,627,887
Inventory
$2,693,926
Purchases of property and
equipment
$525,007
Acquisition of patents
$105,091
Change in fair value of
warrants liabilities
-$731,000
Lease liabilities
-$517,967
Change in fair value of
conversion option...
-$503,000
Accounts receivable
$128,227
Other liabilities
-$23,178
Sales
$2,293,313
Loss before income
taxes
-$18,626,590
Income tax expense
$1,297
Canceled cashflow
$2,293,313
Total operating
expenses
$19,009,582
Total other expense,
net
-$1,037,921
Cost of sales
(excluding depreciation...
$872,400
Total research and
development expense
$7,577,704
General and
administrative expense
$6,646,037
Sales and marketing
expense
$4,443,807
Depreciation and
amortization expense
$342,034
Other research and
development expenses
$5,504,933
Research and development
expense
$2,072,771
Back
Back
Cash Flow
source: myfinsight.com
FEMASYS INC (FEMY)
FEMASYS INC (FEMY)